Federal Peptide & Compounding Defense

Why the Peptide Industry Is a Federal Target Right Now

Federal enforcement against the peptide industry is no longer a possibility, it is a coordinated, active campaign. The FDA, the DOJ, and HHS-OIG are working together to dismantle the gray-market peptide ecosystem that grew up around semaglutide, tirzepatide, BPC-157, and a long list of research peptides marketed for human use without FDA approval.

The trigger was the FDA's 2025 decision to remove semaglutide and tirzepatide from the drug shortage list, ending the legal cover that allowed §503A and §503B pharmacies to compound GLP-1 analogs at scale. Compounders who kept producing lost their statutory safe harbor. Online vendors who shipped "research only" peptides for years lost the implicit tolerance the FDA had extended while it built cases. The Amino Asylum raid and the Peptide Sciences shutdown were the first visible pulls of a much longer thread.

If you run a compounding pharmacy, med spa, weight-loss clinic, online peptide store, hormone optimization practice, or wellness brand that has touched semaglutide, tirzepatide, GLP-1 analogs, growth hormone secretagogues, or research peptides, you are operating inside a live enforcement zone.

The Statutes Federal Prosecutors Are Using

Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 331. Selling, distributing, or introducing an unapproved new drug into interstate commerce is a misdemeanor on the first offense and a felony with intent to defraud or mislead. Penalties under § 333 reach three years per count, and ten years where the government alleges fraudulent intent. The FDCA is the statutory backbone of nearly every peptide prosecution.

Wire Fraud, 18 U.S.C. § 1343. Every Stripe transaction, every Shopify order, every wire transfer for product, every email marketing campaign becomes a separate wire fraud count when prosecutors can show a scheme to defraud customers or regulators. A high-volume online peptide vendor can be charged with dozens of counts, each carrying twenty years.

Conspiracy, 18 U.S.C. § 371. Conspiracy charges allow the government to sweep in pharmacy owners, compounders, marketing partners, fulfillment operators, and physician medical directors as co-defendants, even when their individual role looks limited.

Money Laundering, 18 U.S.C. §§ 1956, 1957. Once the FDCA and wire fraud predicates are established, every deposit, every transfer to an LLC, every payment to a fulfillment vendor becomes a potential money laundering count. This is how prosecutors stack exposure to compel cooperation.

How These Cases Develop

Peptide investigations almost always start with FDA enforcement rather than with the FBI. The pattern is consistent: an FDA inspection of a compounding pharmacy or warehouse produces a Form 483, which becomes a warning letter, which gets referred to the FDA Office of Criminal Investigations (OCI). OCI loops in HHS-OIG and the DOJ's Consumer Protection Branch. By the time a federal grand jury is empaneled, the government has shipping records, payment processor data, social media advertising history, and customer correspondence going back years.

The marketing record is the prosecution's strongest evidence. Instagram posts, TikTok ads, podcast appearances, influencer codes, and website copy that markets peptides "for muscle growth" or "for weight loss" become the centerpiece of intent proof. The "research use only" disclaimer is not a defense when the marketing and the customer base contradict it.

Compounding pharmacies face a narrower escape route. The §503A and §503B safe harbors are technical. Whether a pharmacy compounded patient-specifically, whether the API was on the FDA bulk substances list, whether USP monographs existed, whether the drug shortage exception applied, each of these is a factual battle. We litigate them on the merits, not on rhetoric.

Our Defense Approach

AMC Defense Law has built peptide defense capability from the ground up as the enforcement wave has accelerated. We know how FDA OCI builds cases, how DOJ Consumer Protection charges them, and where the prosecution theories break down.

Pre-indictment intervention. If you have received a Form 483, a warning letter, an FDA subpoena, or an FBI/HHS-OIG visit, the criminal case is in development but charges are not yet filed. Early counsel can negotiate scope, control document production, and in some cases resolve the matter civilly rather than criminally. This window is the most valuable one in a peptide case.

Statutory defense. §503A and §503B compounding authority is a defense on the merits when the facts support it. We work with regulatory experts who can credibly testify about bulk substance list eligibility, USP monograph status, and shortage exception applicability. Most peptide indictments contain at least one count that fails statutory analysis.

Intent defense. FDCA felony counts and wire fraud counts both require proof of intent. Reliance on counsel, reliance on the disclaimer ecosystem the industry built over a decade, and the absence of a clear regulatory line for years are all part of the intent record. Good faith is a defense.

Parallel proceedings. FDA, DEA, state pharmacy boards, state medical boards, and civil class actions all run alongside the federal criminal case. We coordinate across all tracks because losing a pharmacy license or a DEA registration can be as costly as the criminal exposure itself.

If you or your loved ones have been arrested, raided, or contacted by federal investigators regarding peptides, semaglutide compounding, or online peptide sales, call Aaron M. Cohen, 24 hours a day to get help.